GALT Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 22:00):

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases...

Stats
Tagesvolumen	173 828
Durchschnittsvolumen	153 496
Marktkapitalisierung	213.57M
EPS	$0 ( 2024-04-04 )
Nächstes Ertragsdatum	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.66
ATR14	$0.0130 (0.38%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-24	Lewis Joel	Buy	1 000	Common Stock
2023-12-31	Czirr James C	Buy	0
2024-04-22	Czirr James C	Sell	21 323	Common Stock
2024-04-23	Czirr James C	Sell	3 677	Common Stock
2024-04-22	Freeman Kevin D	Buy	2 500	Common Stock

INSIDER POWER
24.13
Last 97 transactions
Buy: 4 256 891 \| Sell: 2 389 317

Volumen Korrelation

Lang: 0.23 (neutral)

Kurz: -0.75 (moderate negative)

Signal:(40.806) Neutral

Galectin Therapeutics Inc Korrelation

10 Am meisten positiv korreliert
BRACU	0.946
KIN	0.945
ALGM	0.929
ACVA	0.929
NCAC	0.925
CLBT	0.921
PEGA	0.92
NSIT	0.92
AMYT	0.919
SRRA	0.919

10 Am meisten negativ korreliert
DCRC	-0.928
AHPI	-0.923
IMV	-0.922
NCBS	-0.921
TENX	-0.92
LAWS	-0.919
CFMS	-0.919
TSHA	-0.918
VWE	-0.917
SGLB	-0.914

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Galectin Therapeutics Inc Korrelation - Währung/Rohstoff

0.12
( neutral )

0.70
( moderate )

0.00
( neutral )

0.64
( weak )

-0.24
( neutral )

-0.71
( moderate negative )

Galectin Therapeutics Inc Finanzdaten

Annual	2023
Umsatz:	$0
Bruttogewinn:	$-33 000.00 (0.00 %)
EPS:	$-0.680

FY	2023
Umsatz:	$0
Bruttogewinn:	$-33 000.00 (0.00 %)
EPS:	$-0.680

FY	2022
Umsatz:	$0
Bruttogewinn:	$-32 000.00 (0.00 %)
EPS:	$-0.660

FY	2021
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.520

Financial Reports:

No articles found.

Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.